Price range: $44.00 through $74.00 / 10 Vials
Semax is a high-potency synthetic heptapeptide derived from a fragment of the Adrenocorticotropic Hormone (ACTH 4-10). It is a premier nootropic and neuroprotective agent designed to enhance cognitive performance under stress, fatigue, or injury. Unlike psychostimulants, Semax works by optimizing the brain’s natural chemical balance, promoting intense mental focus, improved memory consolidation, and resilience against oxidative stress in neuronal tissues.
Amino Acid Sequence Met-Glu-His-Phe-Pro-Gly-Pro
Molecular Formula$C_{37}H_{51}N_{9}O_{10}S$
Molecular Weight 813.9 g/mol
PubChem CID 122178
CAS Number 80714-61-0
Vial Size 3ml (or standard 2ml/5ml vials)
Contents Lyophilized powder, white/off-white color
| Size | 10mg, 5mg |
|---|---|
| Mechanism of Action | BDNF & NGF Elevation: Semax significantly increases the levels of Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF), which are essential for neuroplasticity and the survival of existing neurons. Melanocortin System Activation: It interacts with the melanocortin receptors in the central nervous system, influencing learning processes and inflammatory responses in the brain. Neuroprotection: It prevents the breakdown of enkephalins and protects neurons from "excitotoxicity" (damage caused by overactivation) and hypoxia (lack of oxygen). Dopamine & Serotonin Modulation: Semax subtly modulates the levels of dopamine and serotonin, helping to improve mood and motivation without the "crash" associated with stimulants. |
| Storage & handling | Storage:Store the lyophilized vial in a cool, dry area protected from direct sunlight. |
All products on this site are for laboratory research, development, or analytical use only; they are NOT FOR HUMAN CONSUMPTION, medical, diagnostic, cosmetic, or veterinary applications.
These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat, or prevent any disease. Genixpep is not a compounding or outsourcing facility under sections 503A/503B of the FD&C Act.
